A critical evaluation of contemporary literature regarding the role of big data, artificial intelligence, and digital technologies in precision cardio-oncology care and survivorship, emphasizing innovative and groundbreaking endeavors.

Artificial intelligence (AI) algorithm models can automate the risk assessment process and augment current subjective clinical decision tools. AI, particularly machine learning (ML), can identify medically significant patterns in large data sets. Machine learning in cardio-oncology care has great potential in screening, diagnosis, monitoring, and managing cancer therapy-related cardiovascular complications. To this end, large-scale imaging data and clinical information are being leveraged in training efficient AI algorithms that may lead to effective clinical tools for caring for this vulnerable population. Telemedicine may benefit cardio-oncology patients by enhancing healthcare delivery through lowering costs, improving quality, and personalizing care. Similarly, the utilization of wearable biosensors and mobile health technology for remote monitoring holds the potential to improve cardio-oncology outcomes through early intervention and deeper clinical insight. Investigations are ongoing regarding the application of digital health tools such as telemedicine and remote monitoring devices in enhancing the functional status and recovery of cancer patients, particularly those with limited access to centralized services, by increasing physical activity levels and providing access to rehabilitation services.

In recent years, advances in cancer survival have increased the prevalence of patients experiencing cancer therapy-related cardiovascular complications. Traditional cardio-oncology risk categorization largely relies on basic clinical features and physician assessment, necessitating advancements in machine learning to create objective prediction models using diverse data sources. Healthcare disparities may be perpetuated through AI algorithms in digital health technologies. In turn, this may have a detrimental effect on minority populations by limiting resource allocation. Several AI-powered innovative health tools could be leveraged to bridge the digital divide and improve access to equitable care.

Ferroptosis is a novel form of cell death characterised by iron overload and lipid peroxidation. It is closely associated with many diseases, including cardiovascular diseases, tumours, and neurological diseases. The use of natural chemicals to modulate ferroptosis is of great concern because of the critical role ferroptosis plays in disease. The main active ingredient in green tea is epigallocatechin gallate (EGCG), which is the most abundant catechin in green tea. EGCG shows a wide range of biological and therapeutic effects in various diseases, including anti-inflammatory, antioxidant, anticancer, and cardioprotective.

The purpose of this article is to summarise the existing information on the relationship between EGCG and ferroptosis.

Articles related to EGCG and ferroptosis were searched in PubMed and Web of Science databases, and the literature was analysed.

EGCG could improve ferroptosis-related diseases and affect the development of ferroptosis by regulating the nuclear factor erythroid 2-related factor 2, autophagy, microRNA, signal transducer and activator of transcription 1, and protein kinase D1 signalling pathways.

The objective of this study was to provide an overview of the current practice of patient-reported outcome (PRO) assessments in trials investigating treatment with BRAF inhibitors in patients with advanced melanomas. In addition, we extracted information on symptomatic adverse events (AEs) reported by clinicians to inform future PRO measurement strategies. For our systematic scoping review, we investigated randomized controlled trials (RCTs) evaluating treatment with BRAF inhibitors that had a primary, secondary or exploratory PRO endpoint and were indexed on PubMed. Two independent reviewers extracted information on general RCT characteristics, clinical results (e.g. survival, treatment response and symptomatic AEs) and the PRO measurement and results. Quality of PRO reporting using the CONSORT-PRO checklist was also assessed. We identified nine RCTs meeting the inclusion criteria, in which PROs were secondary or exploratory endpoints. In all trials but one, PROs were measured with the generic EORTC QLQ-C30 questionnaire. The quality of PRO reporting showed substantial variation across the different types of information, with information on handling of missing data and on PRO hypotheses lacking most frequently. Our analysis identified 29 relevant symptomatic AEs that could be reported directly by patients. Our findings may inform the planning of the PRO component of future RCTs, in particular regarding what symptoms and AEs should be covered by PRO measures to provide a comprehensive assessment of treatment tolerability. Our results also indicate a need for improving the quality of PRO reporting, to maximize the impact of PRO findings in real-word practice.

In this study, we aimed to investigate disparities in the tumor immune microenvironment (TME) between primary and metastatic malignant melanoma (MM) using single-cell RNA sequencing (scRNA- seq ) and to identify metastasis-related T cell marker genes (MRTMGs) for predicting patient survival using machine learning techniques. We identified 6 distinct T cell clusters in 10×scRNA-seq data utilizing the Uniform Manifold Approximation and Projection (UMAP) algorithm. Four machine learning algorithms highlighted SRGN, PMEL, GPR143, EIF4A2, and DSP as pivotal MRTMGs, forming the foundation of the MRTMGs signature. A high MRTMGs signature was found to be correlated with poorer overall survival (OS) and suppression of antitumor immunity in MM patients. We developed a nomogram that combines the MRTMGs signature with the T stage and N stage, which accurately predicts 1-year, 3-year, and 5-year OS probabilities. Furthermore, in an immunotherapy cohort, a high MRTMG signature was associated with an unfavorable response to anti-programmed death 1 (PD-1) therapy. In conclusion, primary and metastatic MM display distinct TME landscapes with different T cell subsets playing crucial roles in metastasis. The MRTMGs signature, established through machine learning, holds potential as a valuable biomarker for predicting the survival of MM patients and their response to anti-PD-1 therapy.

To explore the dynamic and parametric characteristics of [18F]F-FAPI-42 PET/CT in lung cancers.

Nineteen participants with newly diagnosed lung cancer underwent 60-min dynamic [18F]F-FAPI-42 PET/CT. Time-activity curves (TAC) were generated for tumors and normal organs, with kinetic parameters (K1, K2, K3, K4, Ki) calculated. A new parameter, the K ratio (K1 + K3)/(K2 + K4), was introduced to measure net uptake efficiency.

In primary tumor (PT), [18F]F-FAPI-42 uptake showed a gradual increase followed by a plateau, contrasting with organs like the thyroid and pancreas, which showed rapid uptake and continuous washout. Compared to non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) lesions reached the plateau earlier (11 min vs. 14 min) but had a lower uptake. During the plateau phase, [18F]F-FAPI-42 demonstrated slight washout in SCLC, whereas its uptake increased slightly in NSCLC. Lymph node and distant metastases exhibited similar TAC profiles to primary tumors. Kinetic modeling revealed that an irreversible two-compartment model (irre-2TCM) best represented the pharmacokinetics of [18F]F-FAPI-42 in lung cancer, whereas re-2TCM was better suited for the pancreas and thyroid. Lower K1, K2, K3 and K4 were observed in PT compared to those in the pancreas and thyroid (P < 0.05), however, the K ratio in PT was found to be 2-3 times higher. SCLC had lower Ki and SUVmean than NSCLC (P < 0.05). Kinetic parameter differences were also observed between PT and metastatic lesions. Larger metastatic lymph nodes exhibited higher K1, Ki, and K ratio than smaller ones.

Lung cancers exhibit distinct [18F]F-FAPI-42 dynamic and kinetic characteristics compared to the thyroid gland and pancreas. Differences were also observed between SCLC and NSCLC, primary and metastatic lesions, as well as larger versus smaller lesions. These findings provide valuable insights into the in vivo pharmacokinetics of [18F]F-FAPI-42, potentially improving the diagnosis of lung cancer.

ChiCTR2100045757. Registered April 24, 2021 retrospectively registered, http//www.chictr.org.cn.

Early cancer detection is crucial for improving patient survival rates. However, current single-biomarker detection methods often face challenges, such as insufficient sensitivity, poor accuracy, and false positives. To address these issues, we report a dual-functionalized glass micropipet sensor (DFMS) capable of simultaneously detecting two cancer biomarkers, nucleic acids and proteins. The inner surface of the sensor is functionalized with amino-modified silicon nanowires (SiNWs) to capture disease-related miRNAs, enabling ionic-current-based detection, while the outer surface is decorated with gold nanoparticles to anchor specific protein aptamers for Raman-based detection. This dual-functionalization significantly enhances the sensitivity and selectivity by combining ionic current amplification with plasmonic Raman signal enhancement. The sensor achieves detection limits of 1 aM for miRNAs and 0.001 ng/mL for proteins, with minimal mutual interference between the two detection modes, ensuring accurate and independent detection. Validation with prostate cancer biomarkers miRNA-1246 and PSA, as well as gastric cancer biomarkers miRNA-106a and CD44, demonstrates its outstanding sensitivity, selectivity, stability, and broad applicability, providing a novel approach for early cancer detection with significant clinical implications.

Globally, cancer is the top cause of mortality, placing a heavy load on the medical system. One of the first known secondary metabolites is curcumin, a bioactive substance. This study aims to emphasize the chemopreventive and chemotherapeutic properties of curcumin and its derivatives, therefore, offering important insights for the possible creation of certain supplemental medications for the treatment of different cancers. Electronic Google databases, including Google scholar, ResearchGate, PubMed/Medline, and ScienceDirect, were searched to gather pertinent data about the chemopreventive and chemotherapeutic effects of curcumin and its derivatives. Various studies have revealed a diverse array of significant biological effects. The majority of investigations pertaining to the potential anticancer effects and associated processes are currently in the experimental preclinical stage and lack sufficient clinical trial data to validate their findings. Clinical research is further needed to clarify the molecular processes and specific targeted action of curcumin and its derivatives, as well as their potential for toxicity and side effects in humans, in order to open up new therapeutic avenues for treating cancer.

Leukemia is a kind of cancer characterized by the proliferation of abnormal, immature White Blood Cells (WBCs) produced in the bone marrow, which subsequently circulate throughout the body. Prompt leukemia diagnosis is vital in determining the optimal treatment plan, as different types of leukemia require distinct treatments. Early detection is therefore instrumental in facilitating the use of the most effective therapies. The identification of leukemia cells from microscopic images is considered a challenging task due to the complexity of the image features. This paper presents a deep learning neural network approach that utilizes the Particle Swarm Optimization (PSO) method to diagnose leukemia cell disease from microscope images. Initially, deep learning is employed to extract features from the leukemia images, which are then optimized by the PSO method to select the most relevant features for machine learning. Three different machine learning algorithms, namely Decision Tree (DT), Support Vector Machine (SVM), and K-Nearest Neighbors (K-NN) methods, are utilized to analyze the selected features. The results of the experiments demonstrate PSO accuracies of 97.4%, 92.3%, and 85.9% for SVM, K-NN, and DT algorithms with GoogLeNet, respectively. The proposed method achieved accuracies of 100%, 94.9%, and 92.3% for SVM, K-NN, and DT methods respectively, with Ant Colony Optimization (ACO) feature extraction and ResNet-50 employed as revealed by the experimental results. These findings suggest that the proposed approach is a promising tool for accurate diagnosis of leukemia cell disease using microscopic images.

Patients with vertebral metastases often experience spinal instability, chronic pain, and psychological distress, all of which can significantly reduce quality of life. Spinal instability, measured by the Spinal Instability Neoplastic Score (SINS), may exacerbate functional impairment and emotional distress, underscoring the potential benefit of personalized recovery interventions.

This prospective, observational study investigated the impact of personalized recovery interventions on spinal instability, psychological distress, and quality of life in oncological patients with vertebral metastases.

The experimental group received tailored rehabilitation strategies, while the control group underwent standard oncological care. Spinal instability was assessed using the Spinal Instability Neoplastic Score (SINS), psychological distress was measured with the Hopelessness Depression Symptom Questionnaire (HDSQ), and quality of life was evaluated using the European Quality of Life-5 Dimensions (EQ-5D). The experimental group demonstrated significantly lower mean SINS scores, indicating reduced spinal instability, and lower HDSQ scores, suggesting decreased psychological distress. They also exhibited improvements in mobility, self-care, usual activities, and anxiety/depression dimensions of the EQ-5D. Furthermore, the experimental group had longer survival times, lower fracture rates, and reduced prevalence of osteoporosis, anemia, and vomiting. These findings underscore the potential benefits of integrating physical and psychological rehabilitation into routine oncological management.

Personalized recovery interventions appear to enhance functional independence, emotional well-being, and overall quality of life in patients with vertebral metastases. Future research should focus on longitudinal, multicenter, randomized controlled trials to confirm these findings and further elucidate the complex interplay between spinal instability, psychological distress, and functional recovery.

We evaluated the effectiveness of the US Health and Retirement Study (HRS) in representing middle-aged and older cancer survivors by comparing individual- and county-level characteristics with those of a comparable cohort in Surveillance, Epidemiology, and End Results (SEER).

We identified incident cancer survivors aged ≥ 50 years in the HRS and SEER biennially from 2000 to 2020. We calculated proportions of individual- level and county-level sociodemographic attributes for the sampling-weighted HRS and SEER. We calculated the standardized differences (SD) between the HRS and SEER, with an SD of ≥ 0.1 indicating a meaningful difference.

Cancer survivors in the HRS and SEER had similar sociodemographic characteristics, with some exceptions. Across most years, the HRS had a lower proportion of cancer survivors in the younger baseline age group (e.g., in 2020, 1.3% in HRS vs. 7.4% in SEER for ages 50-54), but a higher proportion of non-Hispanic White (e.g., in 2020, 75.7% in HRS, 68.3% in SEER), and married (e.g., in 2020, 59.5% in HRS, 53.2% in SEER), all with SD ≥ 0.1. The general populations of their data collection areas were similar, while the HRS over-represented counties with a higher proportion of Hispanic residents.

The sociodemographic profiles of middle-aged and older cancer survivors in the HRS and SEER were similar, with some minor exceptions, reflecting their distinct objectives and data collection methodologies. Understanding the comparability between HRS and SEER is crucial for ensuring that HRS data can reliably inform cancer survivorship research across the US population while providing additional longitudinal aging and covariates data.

The increasing efficacy of cancer therapies has significantly improved survival rates, but it has also highlighted the prevalence of cancer-therapy-related cardiac dysfunction (CTRCD). This review provides a comprehensive overview of the identification, monitoring, and management of CTRCD, a condition resulting from several treatments, such as anthracyclines, HER2-targeted therapies, target therapies, and radiotherapy. The paper includes a discussion of the mechanisms of CTRCD associated with various cancer treatments. Early detection through serum biomarkers and advanced imaging techniques is crucial for effective monitoring and risk stratification. Preventive strategies include pharmacological interventions such as ACE inhibitors/angiotensin receptor blockers, beta-blockers, and statins. Additionally, novel agents like sacubitril/valsartan, sodium-glucose co-transporter type 2 inhibitors, and vericiguat show promise in managing left ventricular dysfunction. Lifestyle modifications, including structured exercise programs and optimized nutritional strategies, further contribute to cardioprotection. The latest treatments for both asymptomatic and symptomatic CTRCD across its various stages are also discussed. Emerging technologies, including genomics, artificial intelligence, novel biomarkers, and gene therapy, are paving the way for personalized approaches to CTRCD prevention and treatment. These advancements hold great promise for improving long-term outcomes in cancer patients by minimizing cardiovascular complications.

This study aimed to assess the accuracy of the Node-RADS scoring system in assessing metastatic lymph node (LN) involvement in patients with head and neck squamous cell carcinoma (HNSCC), a critical factor for treatment planning and prognosis.

A retrospective analysis was conducted on 42 HNSCC patients who underwent preoperative MRI and lymph node dissection. Two radiologists independently evaluated the MRI scans using the Node-RADS system, and the results were compared with postoperative histopathological findings. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and overall accuracy of Node-RADS were calculated, considering LNs with Node-RADS scores of 4 and 5 as positive. LN features such as size, texture, necrosis, border irregularity, and shape were analyzed for their correlation with metastatic involvement. Irregular/ill-defined borders were also evaluated for the detection of Extranodal extension (ENE+).

Out of 118 LNs assessed, 26 (22.03 %) were metastatic (N+), and 8 (7.78 %) were ENE+. Node-RADS demonstrated a sensitivity of 61.54 %, specificity of 89.69 %, PPV of 76.19 %, NPV of 89.69 %, and an overall accuracy of 87.29 %. Significant correlations were observed between LN characteristics like necrosis, border irregularity, shape, and histopathological results (p < 0.0001).

The Node-RADS system exhibited high specificity and accuracy in identifying metastatic LNs in HNSCC patients, making it a promising tool for standardizing preoperative imaging assessments. However, further studies are needed to validate its application and improve its integration with advanced imaging techniques for enhanced diagnostic precision.

Oxidative stress is a key factor in melanoma progression, making it an important therapeutic target. This study explored the effects of tangeretin, a citrus-derived flavonoid, on human melanoma A375 cells and its underlying mechanisms. A375 cells were treated with tangeretin at various concentrations. The effects of tangeretin on cell proliferation, migration, invasion, and apoptosis were assessed using MTT, wound healing, Transwell invasion, and flow cytometry assays, respectively. Oxidative stress markers, including reactive oxygen species (ROS), malondialdehyde (MDA), glutathione (GSH), and superoxide dismutase (SOD), were evaluated. Western blot was used to measure the expression levels of key proteins in the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway and apoptosis-related markers. The results showed that tangeretin significantly inhibited cell proliferation in a dose-dependent manner, induced apoptosis by increasing the Bax/Bcl-2 ratio, and suppressed cell migration and invasion. Additionally, tangeretin reduced oxidative stress by decreasing ROS and MDA levels while enhancing GSH content and SOD activity. Mechanistically, tangeretin activated the Nrf2 signaling pathway, increasing the expression of Nrf2 and its downstream antioxidant proteins heme oxygenase-1, quinone oxidoreductase 1, and γ-Glutamylcysteine synthetase. These findings suggest that tangeretin exerts anti-cancer effects on melanoma cells by regulating oxidative stress, inhibiting proliferation and metastasis, and inducing apoptosis via the Nrf2 pathway. Tangeretin may serve as a promising candidate for melanoma treatment.

Bile acids promote the progression of colon adenocarcinoma (COAD), and ursodeoxycholic acid (UDCA) is a key drug in promoting bile acid excretion, but its role in COAD unclear. Our study aims to investigate the relationship between COAD and bile acid metabolism and to assess the feasibility of UDCA for the treatment of COAD.

Firstly, biological targets closely related to COAD were identified: Based on the cancer genome atlas (TCGA) database, the core genes of COAD were obtained by differential expression analysis and weighted gene-coexpression network analysis (WGCNA), and subjected to gene ontology (GO) function annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Secondly, finding a drug by target, after identifying UDCA as a candidate drug, the feasibility of UDCA in treating COAD was verified in reverse: Using databases to collect potential targets for COAD and UDCA, and the intersecting genes were the potential targets for UDCA to exert anti-tumor effects. Then Autodock was used for molecular docking to analyze the interaction between UDCA and core target proteins. Finally, experimental validation was performed: MTT assay, wound healing, transwell migration, and angiogenesis assays were used to detect the effects of UDCA on cell proliferation, migration, invasion, and neovascularization.

2064 differential genes were screened from TCGA. WGCNA obtained the module most relevant to CRC, containing 493 genes. KEGG analysis found that overlapping genes were mainly concentrated in bile acid metabolic pathways. A total of 26 UDCA anti-tumor targets were obtained in database, and 5 core targets were selected by STRING database and Cytoscape software: TNF, CYP27B1, MDM2, MMP2, CASP3. Molecular docking results showed that UDCA had good binding activity with the core targets. In vitro experiment showed UDCA effectively inhibited the proliferation, migration, invasion and neovascularization in colon cancer cells.

The antitumor activity of ursodeoxycholic acid may be related to cell apoptosis, proliferation, migration and vascular neogenesis.

To compare early recurrence patterns, safety, survival and investigate the clinical risk factors of early recurrence (ER) after liver resection or thermal ablation (TA) for patients with colorectal liver metastases (CRLM) with number ≤ 5 and largest diameter ≤ 3 cm.

This retrospective study included patients with CRLM who underwent liver resection or TA between January 2016 and December 2021 at two hospitals in China. The Kaplan-Meier method and log-rank test were used to assess recurrence-free survival (RFS) and overall survival (OS). Risk factors for ER were analysed using univariate and multivariate Cox regression analyses.

303 patients with 632 liver metastases were enrolled. The most common early recurrence pattern was intrahepatic recurrence (IHR) in resection group and TA group. There was no significant difference in 6-month RFS rate (65.81% vs 66.23%) and median OS (P = 0.10) between two groups. Patients without ER had better OS than those with ER (P < 0.05). The incidence of serious complications (P = 0.013), length of hospitalization (P < 0.01), and albumin-bilirubin (ALBI) score (P = 0.038) in TA group were significantly better than resection group. The diameter of liver metastases (HR: 4.89, 95% CI: 1.16-20.60; P = 0.031) and clinical risk score (CRS) (HR: 1.86, 95% CI: 1.06-3.25; P = 0.029) were independent risk factors for ER.

For CRLM with largest diameter ≤ 3 cm and number ≤ 5, the efficacy of receiving resection or TA is comparable, and the safety of TA is better. TA may be considered as the first-line local treatment option for patients with CRLM.

The WHO Global Initiative for Childhood Cancer will likely increase the number of childhood cancer survivors in resource-poor countries. This study explored survivorship care in Kenya through parental reports on late effects and the follow-up needs of childhood cancer survivors. Parents of Kenyan childhood cancer survivors (under 18 years old) who completed treatment for at least one year were interviewed using semi-structured questionnaires from 2021 to 2022. Parents of 54 survivors were interviewed. Survivors had solid tumors (52%) and hematological tumors (48%). Most (52%) received chemotherapy combined with either surgery or radiotherapy. Many survivors (72%) experienced symptoms according to their parents. The most prevalent symptoms were pain (37%), fatigue (26%), and ocular problems (26%). Eleven percent of parents observed limitations in the daily activities of the survivors. Parents of survivors with two or more symptoms were more likely to rate symptoms as moderate to severe (p = 0.016). Parents expressed concern about late effects (48%). Only 28% were informed about late effects at the hospital, despite 87% indicating they would have welcomed this information. Follow-up care was deemed important by 98%. Recommendations included providing education about late effects and organizing survivor meetings. Survivorship clinics should be established to ensure that follow-up information and care are accessible.

Colorectal cancer (CRC) poses a significant clinical challenge because of drug resistance, which can adversely impact patient outcomes. Recent research has shown that abnormalities within the tumor microenvironment, especially hyperglycemia, play a crucial role in promoting metastasis and chemoresistance, and thereby determine the overall prognosis of patients with advanced CRC.

This study employs data mining and consensus molecular subtype (CMS) techniques to identify pitavastatin and atorvastatin as potential agents for targeting high glucose-induced drug resistance in advanced CRC cells. CRC cells maintained under either low or high glucose conditions were established and utilized to assess the cytotoxic effects of pitavastatin and atorvastatin, both with and without 5-fluorouracil (5-FU). CRC 3D spheroids cultured were also included to demonstrate the anti-drug resistance of pitavastatin and atorvastatin.

A bioinformatics analysis identified pitavastatin and atorvastatin as promising drug candidates. The CMS4 CRC cell line SW480 (SW480-HG) was established and cultured under high glucose conditions to simulate hyperglycemia-induced drug resistance and metastasis in CRC patients. Pitavastatin and atorvastatin could inhibit cell proliferation and 3D spheroid formation of CMS4 CRC cells under high glucose conditions. In addition, both pitavastatin and atorvastatin can synergistically promote the 5-FU-mediated cytotoxic effect and inhibit the growth of 5-FU-resistant CRC cells. Mechanistically, pitavastatin and atorvastatin can induce apoptosis and synergistically promote the 5-FU-mediated cytotoxic effect by activating autophagy, as well as the PERK/ATF4/CHOP signaling pathway while decreasing YAP expression.

This study highlights the biomarker-guided precision medicine strategy for drug repurposing. Pitavastatin and atorvastatin could be used to assist in the treatment of advanced CRC, particularly with CMS4 subtype CRC patients who also suffer from hyperglycemia. Pitavastatin, with an achievable dosage used for clinical interventions, is highly recommended for a novel CRC therapeutic strategy.

To evaluate the effects of passive music listening combined with progressive muscle relaxation on anxiety, depression, stress, coping, and quality-of-life in women with breast and gynaecological cancers receiving chemotherapy.

This was an assessor-blinded, randomised wait-list controlled trial. A total of 120 participants were randomly allocated into an intervention group or a wait-list control group. The intervention group received an intervention comprising training on passive music listening and progressive muscle relaxation, with once-daily self-practice at home for 3 weeks. The wait-list control group received the same intervention after the outcome assessment at week 6. All outcome data were collected before (T0) and 3 weeks (T1), 6 weeks (T2), and 12 months (T3) after randomisation. A generalised estimating equations model was used to compare the changes in each outcome at different time points. Process evaluation was conducted using data from the patient's self-report forms and interviews.

The findings indicated that at T1 and T2, the intervention group's reductions in anxiety were significantly larger than those of the control group. Additionally, the intervention group exhibited significantly better decreases in depression at T2, stress at T1, and dysfunctional coping at T2, and a greater improvement in quality-of-life score at T1 and T2 when compared to the control group. Most of the interviewed participants provided positive feedback on the intervention.

The intervention was beneficial for lowering anxiety, depression, and stress and increasing the quality-of-life of women receiving chemotherapy for breast and gynaecological cancers.

The trial was prospectively registered with ClinicalTrials.gov on 9 February 2022 (registration number: NCT05262621).

The aim of this study was to analyze the factors contributing to the development of pneumonia after colorectal cancer (CRC) surgery and to develop a validated nomogram to predict the risk. We retrospectively collected information on patients who underwent radical CRC resection at a single clinical center from January 2011 to December 2021. The information was then randomly assigned to a training cohort and a validation cohort in a 7:3 ratio. Univariate and multivariate logistic regression analysis were performed on the training cohort to identify independent risk factors for the development of pneumonias, which were then included in the nomogram. Validation was performed in a validation cohort, area under the curve (AUC) and calibration curves were used to determine the predictive accuracy and discriminative power of the graphs, and decision curve analysis (DCA) was used to further substantiate the clinical efficacy of the nomogram. A total of 7130 patients were included in the study. Based on multivariate logistic regression analysis of the training cohort, age, sex, preoperative albumin, surgical methods, and surgical time were identified as independent risk factors for the development of pneumonia after CRC surgery, and a nomogram prediction model was established using the above five variables. The AUC was 0.745 in training cohort and 0.773 in validation cohort. This study established a nomogram that is a good predictor of the risk of developing pneumonia after CRC surgery and provided surgeons with a reference for personalized management of patients in the perioperative period.

In this study, we aimed to evaluate the cost-effectiveness of S-1 and oxaliplatin (SOX) plus bevacizumab (Bmab group) compared with SOX plus cetuximab (Cmab group) as a first-line treatment for patients with Kirsten rat sarcoma virus (KRAS) wild-type metastatic colorectal cancer (mCRC) in Japan from the perspective of healthcare payers.

A partitioned survival model was developed using data from the randomized phase II Osaka Multicenter Study Group on Colorectal Cancer-1107 study, which included overall survival, progression-free survival, and treatment regimens for the Bmab and Cmab groups. Treatment costs were estimated from the Japanese medical claims database and the National Health Insurance drug price list. The utilities were derived from the literature. Outcomes were reported as incremental cost, incremental quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER). The willingness-to-pay (WTP) threshold was set at 7.5 million JPY per QALY. The time horizon of the model was set to 20 years. Sensitivity analyses were conducted to assess the uncertainty of the model for various parameters.

Compared with the Cmab group, the Bmab group had an incremental cost of 911,373 JPY (6,528 USD), an incremental effectiveness of 0.79 QALY, and an ICER of 1146,745 JPY (8,215 USD) per QALY. One-way sensitivity analysis showed that the cost of progressive disease treatment in the Bmab group had the greatest impact on the ICER. According to the probabilistic sensitivity analysis, the Bmab group had a 94.9% probability of being cost-effective compared with the Cmab group.

Considering a WTP threshold of 7.5 million JPY (approximately 53,700 USD) per QALY, Bmab might be a cost-effective treatment option for patients with KRAS wild-type mCRC in Japan. Further studies on economic evaluations based on personalized drugs and patient selection based on clinical and genetic information are warranted.

Androgen deprivation therapy (ADT) increases the risk of frailty, falls, and poor physical functioning in older adults with prostate cancer. Detection of frailty is limited to self-report instruments and performance measures, so unbiased tools are needed. We investigated relationships between an unbiased measure - daily life mobility - and ADT history, frailty, fall history, and functioning in older prostate cancer survivors treated with ADT.

This cross-sectional study recruited prostate cancer survivors with a history of ADT from an exercise clinical trial, an academic medical center, and the community. Participants completed performance measures and surveys to assess frailty, fall history, and physical functioning, then wore instrumented socks for up to seven days to continuously monitor daily life mobility. We performed a principal component analysis on daily life mobility metrics and used regression analyses to investigate relationships between domains of daily life mobility and frailty, fall history, and physical functioning.

Participants (N = 99) were aged 73.0 +/- 7.3 years, most were pre-frail or frail (75 %), and 35 % had fallen at least once in the last year. Daily life mobility metrics clustered into four domains: Gait Pace, Rhythm, Activity, and Balance. Worse scores on Rhythm and Activity were associated with increased odds of frailty (odds ratio [OR] 1.59, 95 % confidence interval [CI]: 1.04, 2.49 and OR 1.81, 95 % CI: 1.19, 2.83, respectively). A worse score on Rhythm was associated with increased odds of ≥1 falls in the previous year (OR 1.60, 95 % CI: 1.05, 2.47). Worse scores on Gait Pace, Rhythm, and Activity were associated with worse physical functioning. Mobility metrics were similar between current and past users of ADT.

Continuous passive monitoring of daily life mobility may identify prostate cancer survivors who have developed frailty, falls, and declines in physical functioning.

Doxorubicin (DOX)-induced chemobrain has been reported in several studies. Its main culprit is the induction of massive amounts of reactive oxygen species (ROS), hence triggering damage to brain tissues and thus leading to neuroinflammation. Biochanin A (BIO-A) is known to be an antioxidant, anti-inflammatory, and neuroprotective agent. An in silico study was designed to examine the potential neuroprotective effect of BIO-A. An in vivo study was used to evaluate the modulatory effect of BIO-A on cognitive impairment engendered by DOX. The insilico investigation proved the putative neuroprotective effect of BIO-A. In the in vivo study, BIO-A treatment counteracted DOX-induced memory deficits, as evidenced by improved spatial memory in rats compared to the DOX-only group. BIO-A also reversed DOX-triggered hippocampal neurodegeneration and neuroinflammation, supported by a significant decrease in tissue contents of NF-κB (p65) by 32 % and NLRP3 by 36 % versus the DOX-only group. BIO-A also abrogated DOX-induced neurodegneration, as evidenced by increasing SIRT1 content by 2-fold and BDNF content by 2-fold versus the DOX-only group in hippocampal tissues. In addition, BIO-A ameliorated DOX-augmented apoptosis in the hippocampus, as evidenced by lowering caspase-3 content in the hippocampus by 26 % versus the DOX-only group. Regarding tauopathy, BIO-A reversed DOX-increased tauopathy by 35 % versus the DOX-only group. The neuroprotectant miR-132 was increased by BIO-A in hippocampal tissues by 4-fold, contrary to the DOX-only group. Thus, BIO-A treatment modulated DOX-induced behavioral, histological, and molecular changes in the hippocampi of rats. Further studies are recommended to evaluate BIO-A in early clinical trials for the purpose of protection against chemobrain in cancer patients.

To explore the modulating role of unmet support needs on the relationship between age and the prevalence of cancer-related distress in colorectal cancer (CRC) survivors. Two hundred and forty four participants completed the questionnaires; linear regression and odd ratios were calculated. Both the prevalence of needs and their interaction with age were predictors of cancer-related distress. The risk of significant clinically distress associated with physical and socio/family needs was high in both age subgroups. Higher risk of clinical distress was associated with life perspective, sexual, occupational and health care needs in the younger subgroup and with needs for specific support resources in the older subgroup. In reducing cancer-related distress, two key issues arise: (i) the importance of managing the persistent negative symptoms following CRC treatment in survivors of any age and (ii) the need for a differentiated attention to other care needs based on the survivor's age.

The percentage of people with lung cancer remains high. Given that the majority of NSCLC patients are currently on third-generation clinical agents, the search for a class of highly effective and low-toxicity inhibitors is critical. Hence, in the present study, 24 compounds were synthesized by scaffold hopping with 2-indolone as the parent nucleus. The anti-tumor activity against two human non-small cell lung cancer cell lines (A549 and H1975) was evaluated in vitro using Osimertinib as a positive control drug. Results demonstrated that compound T16 (IC50 = 0.386 ± 0.032 μM) exhibited comparable anti-tumor activity to Osimertinib (IC50 = 0.098 ± 0.006 μM). Moreover, T16 showed a twofold higher selectivity than Osimertinib in normal HEK293 cells. Subsequent studies confirmed that compound T16 inhibited colony formation in both H1975 and A549 cells at concentrations consistent with the initial screening assay results. Additionally, it suppressed migration of H1975 cells, and induced apoptosis while significantly reducing phosphorylation levels of EGFR and AKT proteins. In vivo experiments demonstrated effective tumor suppression after 20 days' treatment with compound T16 in CDX model. RNA sequencing analysis further revealed that compound T16 induced expression of HMOX1 leading to ferroptosis trigger. Additionally, molecular docking results indicate that T16 is chimerized into the mutant protein pocket in an 'arch-bridge' conformation.

Previous studies on cardiovascular disease (CVD) death risk in cancer patients mostly focused on overall cancer, age subgroups and single cancers.

To assess the CVD death risk in non-metastatic cancer patients at 21 cancer sites.

A total of 1,672,561 non-metastatic cancer patients from Surveillance, Epidemiology, and End Results (SEER) datebase (1975-2018) were included in this population-based study, with a median follow-up of 12·7 years. The risk of CVD deaths was assessed using proportions, competing-risk regression, absolute excess risks (AERs), and standardized mortality ratios (SMRs).

In patients with localized cancers, the proportion of CVD death and cumulative mortality from CVD in the high-competing risk group (14 of 21 unique cancers) surpassed that of primary neoplasm after cancer diagnosis. The SMRs and AERs of CVD were found higher in patients with non-metastatic cancer than the general US population (SMR 1·96 [95 %CI, 1·95-1·97]-19·85[95 %CI, 16·69-23·44]; AER 5·77-210·48), heart disease (SMR 1·94[95 %CI, 1·93-1·95]-19·25[95 %CI, 15·76-23·29]; AER 4·36-159·10) and cerebrovascular disease (SMR 2·05[95 %CI, 2·02-2·08]-24·71[95 %CI, 16·28-35·96]; AER 1·01-37·44) deaths. In the high-competing risk group, CVD-related SMR in patients with localized stage cancer increased with survival time but followed a reverse-dipper pattern in the low-competing risk group (7 of 21 cancers). The high-competing risk group had higher CVD-related death risks than the low-competing risk group.

The CVD death risk in patients with non-metastatic cancer varied by cancer stage, site and survival time. The risk of CVD mortality is higher in 14 out of 21 localized cancers (high-competing cancers). Targeted strategies for CVD management in non-metastatic cancer patients are needed.

To assess the impact of the biopsy core length on the discrepancy in Gleason score between biopsy and radical prostatectomy specimens.

Retrospective analysis of clinical data from 247 patients who underwent transperineal prostate biopsy and radical prostatectomy of prostate cancer at our centre from 2022 to 2023. The clinical data included age, pre-biopsy prostate-specific antigen (PSA) levels, prostate volume, number of biopsy needles, number of positive biopsy needles, biopsy core length, biopsy Gleason score and post-radical prostatectomy Gleason score. Statistics were analysed by SPSS26.

On histopathological examination, no changes in the Gleason score were observed in 127 (51.4%) patients, whereas the Gleason score was upgraded in 101 (40.9%) patients and downgraded in 19 (7.7%) patients at radical prostatectomy. Average biopsy core length for Gleason score upgraded on radical prostatectomy (44.3 %, n = 101) was 11.11 ± 1.34 mm compared to 11.88 ± 1.03 mm(p < 0.01)for Gleason score consistent(55.7 %, n = 127). The multivariate logistic regression analysis revealed a significant association between the biopsy core length (P < 0.01, OR = 0.556, 95%CI: 0.429--0.722) and prostate volume (P < 0.05, OR = 0.982, 95%CI: 0.429--0.722), with both factors being significantly correlated with radical prostatectomy Gleason score increase. Furthermore, these variables were identified as independent predictors of radical prostatectomy Gleason score increase and exhibited a negative correlation. The biopsy core length was evaluated using a receiver operating characteristic (ROC) curve, with a cutoff value of 11.4 mm for the accurate diagnosis of prostate cancer (AUC: 0.702, sensitivity: 75.6%, specificity 51.2%, P < 0.001).

The concordance between biopsy and radical prostatectomy may be improved with a longer biopsy core length. To enhance the consistency of Gleason scores between biopsy and radical specimens, it is recommended that the biopsy core length be at least 11.4 mm. Patients with a smaller prostate volume are at a higher risk of experiencing discordant pathological grades between biopsy and radical prostatectomy.

To contribute to the refinement of future physical activity (PA) guidelines, which have remained mostly generic until now, we performed an umbrella review of meta-analyses for PA in cancer survivors.

Medline and Scopus databases were searched in January 2024 for systematic reviews and meta-analyses on the association/effect of any type of PA in every cancer type and for any studied outcome. Statistically significant meta-analyses were categorized into four evidence groups (strong, highly suggestive, suggestive, weak) using pre-established grading criteria.

A total of 102 publications reporting 740 meta-analytic associations were identified, including breast (n = 427), prostate (n = 104), hematological (n = 58), colorectal (n = 79) and lung (n = 54) cancer survivors. Overall, 401 (54 %) associations were nominally statistically significant, of which 16 were categorised as strong, 10 as highly suggestive, and 93 as suggestive evidence. In breast cancer, there was strong or highly suggestive evidence that post-diagnosis PA is associated with lower all-cause mortality, recurrence, cancer-related fatigue, depression, and higher mental health, body strength, aerobic capacity, and weight loss. In prostate cancer, strong evidence was identified for the positive association of PA with cardiovascular fitness, quality of life and fatigue amelioration. In colorectal cancer, strong and highly suggestive evidence supported the association of PA with lower all-cause mortality. In lung cancer, strong evidence supported the association of preoperative combination of breathing exercise and PA with reduced length of hospital stay.

This grading of the entirety of the available evidence can facilitate robust introduction of targeted exercise prescription in oncology care as standard practice.

There are disparities in health behaviors across racial and ethnic groups. However, limited studies focus on cancer survivors' experiences developing and maintaining healthy behaviors, particularly in non-Hispanic Black (NHB) and Hispanic people.

This study aimed to understand the experiences of NHB and Hispanic people affected by cancer in developing and maintaining positive health behaviors beyond a cancer diagnosis.

The data were collected in a mixed-method study through semistructured interviews with 29 NHB and Hispanic cancer survivors between June and October 2022. Conventional content analysis was used.

The lived experiences of cancer survivors were narrated in 3 themes: impact of a cancer diagnosis on oneself, facilitators and barriers to health and health behaviors, and utilization of available sources for health. Facilitators and barriers to health and health behaviors were further explored as biological (eg, symptoms, comorbidities), behavioral (eg, help-seeking behavior, sleep pattern), physical/built (eg, available sources, neighborhood), and sociocultural environment (eg, income, transportation, knowledge, culture, upbringing, household and community composition, social and family network), and healthcare system-related factors (eg, insurance coverage, personal preferences, perceived discrimination, and stigma).

Non-Hispanic Black and Hispanic people, specifically those living in disadvantaged neighborhoods with limited sources or where they feel discriminated and stereotyped, those with limited income and transportation, and those with physical, social, or mental health problems, seemed to have challenges prioritizing health behaviors and maintaining healthy living.

Biological, behavioral, and psychosocial determinants of health behaviors should be addressed through multilevel collaborations among different levels of partners.

While cancer mortality rates in the United States (U.S.) have decreased due to advances in chemotherapy, older adults with cancer face an elevated risk of venous thromboembolism (VTE). This study analyzes trends in cancer-associated VTE mortality among older adults in the U.S.

Using the CDC WONDER multiple cause of death (MCD) database, we reviewed death certificates from 1999 to 2020 to assess cancer-associated VTE mortalities among older adults (≥65 years old). We report age-adjusted mortality rates (AAMRs) per 100,000 persons, along with the average annual percent change (AAPC) using Joinpoint regression.

Over the study period, 175,811 cancer-associated VTE deaths were recorded. The AAMR rose from 16.8 in 1999 to 22.8 in 2020, with an AAPC of +1.4 % (95 % CI: 1.2-1.6; p < 0.001). Males had a higher AAMR (22.2) than females (17.0). Non-Hispanic (NH) Black individuals had the highest AAMR (28.3), followed by NH Whites (19.3), Hispanics (12.0), and NH Asians (7.9). AAMRs were higher in nonmetropolitan areas (19.4) than urban counterparts (19.1). Regionally, the Midwest recorded the highest AAMR at 20.9. States in the top 90th percentile reported double the AAMRs compared to those in the bottom 10th percentile.

Cancer-associated VTE mortality rates are rising among older adults in the U.S., highlighting the need for enhanced screening, aggressive management, and consistent surveillance for VTE in cancer patients at risk.

Microtubules (MTs) have been postulated as one of the molecular targets underlying loss of consciousness induced by inhalational anesthetics. Microtubule-targeting chemotherapy drugs and opioids affect MT stability and function. However, the impact of prolonged administration of these drugs on anesthetic potency and anesthesia induction and emergence times remain unelucidated.

Epothilone D, paclitaxel, vinblastine or opioid morphine were administered alone for a prolonged period (> 2 weeks) to male CD1 mice and their sensitivity to incremental concentrations of isoflurane were examined using loss of righting reflex (LORR) response as a measure of sensivity. The induction and emergence time after administration and termination of fixed concentration of isoflurance (1.2%) were also assessed.

Compared with saline treatment, epothilone D and vinblastine induced a leftward (more sensitive) shift of LORR response curves (95% confidence intervals for EC50: epothilone D, 0.75[0.73, 0.77] vs. saline, 0.97[0.96, 0.98]; vinblastine, 0.74[0.73, 0.75] vs. saline, 0.98[0.97, 0.99]). In contrast, morphine caused a rightward (more resistant) LORR response curve (morphine, 1.16[1.15, 1.17] vs. saline, 0.97[0.96, 0.98]), while paclitaxel produced a marginal but significant rightward shift of LORR (paclitaxel, 1.05[1.03, 1.06] vs. saline, 0.98[0.97, 0.99]). At concentration of 1.2% isoflurane, morphine treatment prolonged (275 ± 50) and vinblastine treatment reduced (96.5 ± 26) the anesthetic induction latency (in second) relative to saline treatment (211 ± 39). The latency of emergence from anesthesia was shorter in morphine (58 ± 20) and vinblastine-treated (98 ± 43) mice compared to saline (176 ± 50) treatment. The induction or emergence latencies of epothilone D or paclitaxel treatment did not differ from saline treatment between groups.

Microtubule-modulating drugs can affect not only sensitivity but also induction and emergence times to inhalational anesthetic isoflurane in mice. This study highlights a possible role of MTDs in modulating anesthetic effects in disparate directions, which has implications for anesthetic concentrations that should be used for induction, maintenance and emergence of anesthesia. These findings in rodents may have relevance to the perioperative care of cancer patients who receive MT-targeting chemotherapy drugs or even opioids for pain for prolonged periods.

The combination of anlotinib with immune checkpoint inhibitors (ICIs) has become a common treatment modality in clinical practice. However, the optimal dose of anlotinib to use remains unclear. We collected patients with advanced non-small cell lung cancer (NSCLC) who received programmed cell death-1 blockade combined with different dose of anlotinib as second-line or later line therapy. Subsequently, the efficacy and safety of the combination therapy as well as subgroup analyses of different doses of anlotinib were analyzed. Cox regression was performed to analyze significant factors correlated with progression-free survival (PFS) and overall survival (OS). A total of 50 eligible patients with NSCLC who received anlotinib combined with ICIs therapy were included, of which 27 received low-dose anlotinib (8 mg), and 23 were administered high-dose anlotinib (12 mg). The median PFS (mPFS) and the median OS (mOS) for all patients were 8.3 months [95% confidence interval (CI): 6.3-10.3] and 17.6 months (95% CI: 16.5-18.7), respectively. Subgroup analyses showed that patients treated with 8 mg of anlotinib plus ICIs had significantly longer mPFS than those treated with 12 mg of anlotinib plus ICIs (8.7 vs 6.7 months, P  = 0.016). The overall incidence of adverse events was 68.0%, and the most common adverse events of all grades were hypertension. Meanwhile, the incidence of adverse events was higher for 12 mg of anlotinib plus ICIs than that of 8 mg of anlotinib plus ICIs (82.6 vs 55.6%, P  = 0.041). Low-dose anlotinib in combination with ICIs for advanced NSCLC may be an effective and well-tolerated option.

Background: Microtubule dynamics play a pivotal role in cancer progression and response to chemotherapeutics. Identifying regulators of microtubule stability can provide new therapeutic targets and predictive biomarkers for cancer treatment. Methods: We investigated the role of ARIH1, an E3 ubiquitin ligase, in breast cancer by analyzing clinical datasets to assess its expression levels and prognostic significance. Functional studies were conducted in breast cancer cell lines to evaluate the impact of ARIH1 depletion on microtubule stability, MAP4 regulation, and paclitaxel sensitivity. Results: Clinical dataset analysis revealed that ARIH1 expression is significantly elevated in breast cancer tissues and correlates with poor prognosis and reduced recurrence-free survival. High ARIH1 expression stratifies patients into high-risk groups, underscoring its potential as a prognostic biomarker. Functional studies demonstrated that ARIH1 loss led to upregulation of MAP4, a microtubule-associated protein, resulting in microtubule stabilization via increased tubulin acetylation and enhanced spindle organization. This stabilization sensitized breast cancer cells to paclitaxel treatment, leading to reduced cell viability, impaired colony formation, and increased apoptosis in ARIH1-deficient cells. Conclusions: Our findings identify ARIH1 as a novel regulator of microtubule dynamics in breast cancer. ARIH1 suppression enhances paclitaxel sensitivity, highlighting its potential as both a therapeutic target and a biomarker for predicting treatment response and patient outcomes in breast cancer.

Ampullary adenocarcinoma is a rare malignant tumor of the gastrointestinal tract. Currently, only a few cases have been reported, resulting in limited information on survival.

To develop a dynamic nomogram using internal and external validation to predict survival in patients with ampullary adenocarcinoma.

Data were sourced from the surveillance, epidemiology, and end results stat database. The patients in the database were randomized in a 7:3 ratio into training and validation groups. Using Cox regression univariate and multivariate analyses in the training group, we identified independent risk factors for overall survival and cancer-specific survival to develop the nomogram. The nomogram was validated with a cohort of patients from the First Affiliated Hospital of the Army Medical University.

For overall and cancer-specific survival, 12 (sex, age, race, lymph node ratio, tumor size, chemotherapy, surgical modality, T stage, tumor differentiation, brain metastasis, lung metastasis, and extension) and 6 (age; surveillance, epidemiology, and end results stage; lymph node ratio; chemotherapy; surgical modality; and tumor differentiation) independent risk factors, respectively, were incorporated into the nomogram. The area under the curve values at 1, 3, and 5 years, respectively, were 0.807, 0.842, and 0.826 for overall survival and 0.816, 0.835, and 0.841 for cancer-specific survival. The internal and external validation cohorts indicated good consistency of the nomogram.

The dynamic nomogram offers robust predictive efficacy for the overall and cancer-specific survival of ampullary adenocarcinoma.

Currently, female breast cancer (BC) represents the highest incidence of cancer globally. This trend has raised significant attention regarding breast cancer young women (BCYW). With advancements in treatment technology, BCYW survivors are living longer; however, the risk of developing or succumbing to a second primary cancer (SPC) has greatly increased. In addition, several factors, including age, menstrual cycle, hormonal changes, obesity, pregnancy, and breastfeeding, interact to influence the development of SPC in BCYW and make its treatment more difficult. This study investigates the relationship between BCYW and SPC, focusing on morbidity trends, pathological genomics, recurrence rates, survival times, treatment modalities, and physiological fertility. Most BCYW involve BRCA pathogenic variants or fall under triple-negative and human epidermal growth factor receptor 2-overexpressing subtypes, increasing the risk of SPC. While there are regional variations in survival time following the diagnosis of an SPC, the long-term survival outcomes remain unfavorable. In addition, the choice of treatment for BCYW survivors has a prolonged cumulative toxic effect. The combination of endocrine therapy and chemotherapy is effective in treating BC, but it simultaneously increases the risk of developing an SPC, specifically endometrial cancer. Furthermore, radiotherapy is associated with a heightened risk of contralateral BC and lung cancer. We aim to address existing gaps in the literature and to enhance awareness of the risks associated with SPC in BCYW, thereby offering valuable insights for clinical diagnosis and treatment.

Skin cutaneous melanoma (SKCM) is a cancer with serious global impact. Long non-coding RNA was previously found to be associated with tumor prognosis. This research focuses on long intergenic non-protein coding (LINC) RNAs, and correlated protein-coding genes (PCGs), to explore their diagnostic and prognostic value, function and mechanism. Gene expression data was obtained from TCGA and Oncomine for analysis; in total there were 458 cases included in this study. LIN00518 and the 10 most highly correlated PCGs were selected to determine the diagnostic and prognostic value. We undertook bioinformatic analysis with LINC00518 and the prognostic-related PCGs in order to explore their molecular mechanism. The Connectivity Map was carried out for pharmacological target prediction and drug selection. Among the top 10 correlated PCGs, trafficking kinesin protein 2 (TRAK2), epilepsy of progressive myoclonus type 2 gene A (EPM2A) and melanocyte inducing transcription factor (MITF) had significant diagnostic value (all AUC > 0.7, P < 0.05). LINC00518, ras association domain family member 3 (RASSF3), cdk5 and Abl enzyme substrate 1 (CABLES1), kazrin, periplakin interacting protein (KAZN), EF-hand calcium binding domain 5 (EFCAB5) and MITF were significantly associated with prognosis (all adjusted P < 0.05). LINC00518 was associated with cell cycle process, melanogenesis, MAPK signaling pathway, cell division and DNA repair(all P < 0.05). Pharmacological targets analysis suggested results acquired eight potential target drugs. Up-regulation of LINC00518 is significantly associated with poor prognosis. TRAK2, EPM2A and MITF had diagnostic significance. RASSF3, CABLES1, KAZN, EFCAB5 and MITF had prognostic significance. This study provided novel biomarkers for SKCM.

Breast cancer (BC) is a predominant malignancy globally, surpassing lung cancer in terms of diagnostic frequency, with an escalating incidence rate in recent decades. Recent studies have investigated the role of protein kinase C zeta (PRKCZ) in diverse cellular processes in cancer biology. In this study, we evaluated the association between PRKCZ and deleterious outcomes in BC and elucidated the mechanisms underlying its expression in breast carcinoma.

The correlation between PRKCZ and survival rates of patients with BC was investigated using The Cancer Genome Atlas database. The methylation status of the PRKCZ promoter was analyzed using the UALCAN database. Furthermore, we investigated the mechanisms underlying PRKCZ inactivation in BC by treatment with transferase inhibitors, methylation-specific polymerase chain reaction (PCR) analysis, western blotting, and luciferase reporter gene assays. The degree of methylation and expression levels of PRKCZ, as regulated by DNA methyltransferase 1 (DNMT1), were quantified using quantitative PCR and western blotting.

Our analysis revealed that decreased expression of PRKCZ in BC was significantly correlated with poor clinical prognosis. Furthermore, we observed that hypermethylation of the PRKCZ promoter contributed to its reduced expression in BC. Notably, DNMT1 has been identified as a critical regulator of PRKCZ methylation.

Our findings elucidate the tumor-suppressive function of PRKCZ and provide insights into the molecular mechanisms underlying its downregulation in BC.

In this article, we comment on the article by Long et al published in the recent issue of the World Journal of Gastrointestinal Oncology. Rectal cancer patients are at risk for developing metachronous liver metastasis (MLM), yet early prediction remains challenging due to variations in tumor heterogeneity and the limitations of traditional diagnostic methods. Therefore, there is an urgent need for non-invasive techniques to improve patient outcomes. Long et al's study introduces an innovative magnetic resonance imaging (MRI)-based radiomics model that integrates high-throughput imaging data with clinical variables to predict MLM. The study employed a 7:3 split to generate training and validation datasets. The MLM prediction model was constructed using the training set and subsequently validated on the validation set using area under the curve (AUC) and dollar-cost averaging metrics to assess performance, robustness, and generalizability. By employing advanced algorithms, the model provides a non-invasive solution to assess tumor heterogeneity for better metastasis prediction, enabling early intervention and personalized treatment planning. However, variations in MRI parameters, such as differences in scanning resolutions and protocols across facilities, patient heterogeneity (e.g., age, comorbidities), and external factors like carcinoembryonic antigen levels introduce biases. Additionally, confounding factors such as diagnostic staging methods and patient comorbidities require further validation and adjustment to ensure accuracy and generalizability. With evolving Food and Drug Administration regulations on machine learning models in healthcare, compliance and careful consideration of these regulatory requirements are essential to ensuring safe and effective implementation of this approach in clinical practice. In the future, clinicians may be able to utilize data-driven, patient-centric artificial intelligence (AI)-enhanced imaging tools integrated with clinical data, which would help improve early detection of MLM and optimize personalized treatment strategies. Combining radiomics, genomics, histological data, and demographic information can significantly enhance the accuracy and precision of predictive models.

The aim of this study was to investigate the joint association of systemic inflammatory response index (SIRI) and sarcopenia with cancer-specific and all-cause mortality in individuals with self-reported cancer.

The study cohort comprised individuals with a self-reported cancer diagnosis from the NHANES database, with data collected between 1999 and 2006 and 2011-2018. The researchers tracked deaths up to 31 December 2019 by linking the relevant records to those held by the (NDI). A weighted sampling design was employed, with participants stratified according to the median value of the SIRI. Cox regression models were employed to assess the association between SIRI, sarcopenia, all-cause mortality, and cancer-specific mortality.

The study cohort comprised 1316 individuals with self-reported cancer. Over a median follow-up period of 9.21 years, 523 all-cause deaths were recorded, including 163 cancer-specific and 360 non-cancer deaths. Adjusting for multiple confounders, elevated SIRI levels were significantly associated with increased risks of all-cause (HR = 1.90 [1.58-2.28]), cancer (HR = 1.88 [1.26-2.78]), and non-cancer mortality (HR = 1.93 [1.54-2.41]). Sarcopenia also emerged as a significant predictor of mortality. Individuals with sarcopenia faced a 50% higher risk of all-cause mortality (HR = 1.50 [1.18-1.91]) and a 54% higher risk of non-cancer mortality (HR = 1.54 [1.11-2.12]). However, the association with cancer mortality was not significant in the fully adjusted model. When both sarcopenia and elevated SIRI were present, the risk was the highest for all-cause (HR = 2.54 [1.92-3.37]), cancer (HR = 2.29 [1.19-4.40]), and non-cancer mortality (HR = 2.63 [1.78-3.89]). Elevated SIRI alone was linked to significant risks for all-cause (HR = 1.91 [1.51-2.42]), cancer (HR = 1.95 [1.28-2.97]), and non-cancer mortality (HR = 1.92 [1.46-2.53]). Sarcopenia alone significantly increased the risk of all-cause mortality (HR = 1.63 [1.01-2.56]) but not cancer mortality.

Our study is the first to demonstrate the joint association between the SIRI and sarcopenia with mortality among individuals with self-reported cancer. These findings underscore the importance of assessing and managing these two factors in individuals with self-reported cancer to reduce the risk of death and improve survival outcomes.

To examine trends in the prevalence of depression and anxiety during the COVID-19 pandemic among US adult cancer patients and survivors (CPS) in comparison to those of non-CPS (NCPS).

National Health Interview Survey 2019-2022 data were analysed using spline logistic regression.

A total of 115 664 participants completed the survey (mean age (SD), 52.8 (18.4) years; 54.3% female; 12.6% CPS). The age-adjusted prevalence of depression significantly increased from 26.53% in 2019 to 29.78% in 2022 among CPS, while that of anxiety increased from 24.02% in 2019 to 28.08% in 2022. Throughout the pandemic, there were consistently significant annual increases in the prevalence of both depression and anxiety with CPS experiencing significantly faster rates of increase compared with NCPS (average annual absolute increase 0.72% in NCPS vs 1.08% in CPS, p<0.01 for depression; 0.98% in NCPS vs 1.35% in CPS, p<0.01 for anxiety). Difficulty in social activity engagement emerged as the primary risk factor for both depression (adjusted OR (aOR), 7.38 (95% CI, 7.04 to 7.73), p<0.01) and anxiety disorders (aOR, 7.58 (95% CI, 7.23 to 7.95), p<0.01). Significant interactions were found between difficulty in social engagement and cancer status on the diagnoses of depression (aOR, 0.72 (95% CI, 0.63 to 0.83), p<0.01) and anxiety (aOR, 0.62 (95% CI, 0.55 to 0.70), p<0.01).

The notably higher prevalence and more rapid increase in rates of depression and anxiety disorders among CPS compared with NCPS underscore the disproportionate impact of the COVID-19 pandemic on CPS and the necessity of prioritising mental health support and interventions for this population.

Anemia is a prevalent issue among cancer survivors, which greatly affects their quality of life and overall prognosis. The Naples Prognostic Score (NPS), an inflammation-based prognostic tool, is increasingly acknowledged for its potential in predicting clinical outcomes. This study aims to assess the correlation between anemia status, prognosis, and NPS in cancer survivors.

This study utilized data from the National Health and Nutrition Examination Survey (NHANES) database spanning from 2003 to 2018, along with death data from the National Death Index (NDI) up to December 31, 2019. A total of 80,312 participants were included, of whom 4,260 were identified as cancer survivors. After applying rigorous exclusion criteria for missing variables, 3,143 participants were retained in the final analysis. NPS was calculated using serum albumin (ALB), total cholesterol (TC), neutrophil to lymphocyte ratio (NLR), and lymphocyte to monocyte ratio (LMR). After adjusting relevant confounding factors, weighted univariable and multivariable logistic regression were utilized to calculate the odds ratios (OR) and 95% confidence intervals (CI). Kaplan-Meier (KM) curves and Log-rank test were employed to compare survival differences among the three patient groups, while Cox proportional regression was utilized to estimate hazard ratio (HR) and 95% CI. Additionally, subgroup analyses were performed to assess the consistency of the outcomes.

Univariable and multivariable analyses indicated positive correlation between NPS and anemia in cancer survivors (P < 0.05). When NPS was treated as continuous variable, crude model showed that higher NPS scores were linked to higher likelihood of anemia in cancer survivors (OR: 1.77, 95% CI: 1.55 - 2.02; P < 0.001), and this association remained significant even after adjusting for all confounding variables (OR: 1.66, 95% CI: 1.45 - 1.90; P < 0.001). Moreover, with Q1 (score = 0) as the reference category, the analysis demonstrated positive association between NPS and the prevalence of anemia in cancer survivors, regardless of whether the model was crude or fully adjusted (P < 0.001). KM analysis indicated that the decline in overall survival from all causes and other causes was significantly more pronounced among anemic cancer survivors in the Q3 (score = 3 or 4) group (P < 0.05). After accounting for all confounding factors, individuals with the highest NPS had HR of 2.46 (95% CI: 1.81 - 3.34) for all-cause mortality. However, there were no significant differences in mortality trends related to cardiovascular or cancer causes (P > 0.05). Subgroup analyses and sensitivity analysis revealed no statistically significant interactions (P for interaction < 0.05).

The study highlights the correlation between higher NPS and an increased prevalence of anemia in cancer survivors, indicating that NPS may serve as a valuable tool for assessing the prognosis of cancer survivors in clinical practice and for guiding interventions aimed at mitigating anemia-related complications.

This study aims to summarize the impact of oral nutritional supplements (ONSs) on mitigating body weight loss (BWL) in patients following surgical treatment for solid tumors.

A systematic and comprehensive search of four major publicly available databases was conducted up to May 2024 to identify studies for inclusion in the analysis. Data from eligible studies were extracted, and pooled mean differences (MD) along with their 95% confidence intervals (CIs) for BWL were computed.

A total of 12 randomized controlled trials (RCTs) with 2,268 participants were finally included. The group receiving oral nutritional supplements demonstrated a statistically significant reduction in weight loss compared to the control group, with a mean difference of 1.11 (95% CI: 0.52-1.70), an I 2 statistic of 97.0%, and a p-value less than 0.01.

The meta-analysis provide evidence that ONSs effectively reduce BWL in postoperative patients with solid tumors. Additionally, ONS with lower daily caloric intake demonstrated superior efficacy in reducing BWL.